Literature DB >> 23445257

Prevalence of hyperprolactinaemia in female premenopausal blood donors.

Macarena Alpañés1, Raúl Sanchón, M Ángeles Martínez-García, Elena Martínez-Bermejo, Héctor F Escobar-Morreale.   

Abstract

OBJECTIVE: The prevalence of asymptomatic hyperprolactinaemia has been widely studied in certain populations such as antipsychotic drugs users, infertile women or patients with primary hypothyroidism, but data on the prevalence of hyperprolactinaemia and macroprolactinaemia in the healthy population are very scarce in the literature. We aimed to obtain an unbiased estimation of the prevalence in premenopausal women of: (i) hyperprolactinaemia and (ii) its aetiology, including macroprolactinaemia and stress-related hyperprolactinaemia, while considering simultaneously the use of hormonal contraceptives.
DESIGN: Prevalence survey.
SUBJECTS: Three-hundred and ninety-three consecutive premenopausal women reporting spontaneously for blood donation. MEASUREMENTS: We performed an exhaustive clinical history and physical examination, establishing the presence of hirsutism, acne, alopecia, menstrual dysfunction and reproductive history. We also measured serum prolactin (PRL) (ruling out macroprolactinaemia when indicated), thyrotrophin, total testosterone, androstendione, sex hormone binding globulin and dehydroepiandrosterone sulphate concentrations.
RESULTS: Serum PRL concentrations were increased in 16 of 393 women (4·1% prevalence, 95% CI: 2·1-6·0). The prevalence of macroprolactinaemia was 0·6% (95% CI: 0-1) in the total female blood donor population and was 12·5% (95% CI: 6-31) among hyperprolactinaemic patients. The remaining hyperprolactinaemic women had stress-related hyperprolactinaemia as the more likely aetiology. Finally, the frequency of hyperprolactinaemia was similar in users and nonusers of hormonal contraceptives (4·5% and 3·9% respectively, P = 0·209).
CONCLUSIONS: The prevalence of hyperprolactinaemia in healthy female blood donors is low and is not influenced by the use of hormonal contraceptives. Pathological causes are very rare with stress-related hyperprolactinaemia and macroprolactinaemia being the most frequent causes of hyperprolactinaemia in these women.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23445257     DOI: 10.1111/cen.12182

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Endocrine autoimmune diseases and female infertility.

Authors:  Aritro Sen; Vitaly A Kushnir; David H Barad; Norbert Gleicher
Journal:  Nat Rev Endocrinol       Date:  2013-11-05       Impact factor: 43.330

Review 2.  Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.

Authors:  Noor Azlin Azraini Che Soh; Najib Majdi Yaacob; Julia Omar; Aniza Mohammed Jelani; Noorazliyana Shafii; Tuan Salwani Tuan Ismail; Wan Norlina Wan Azman; Anis Kausar Ghazali
Journal:  Int J Environ Res Public Health       Date:  2020-11-06       Impact factor: 3.390

3.  Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?

Authors:  Claire Rodier; Blandine Courbière; Sara Fernandes; Marie Vermalle; Bretelle Florence; Noémie Resseguier; Thierry Brue; Thomas Cuny
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-18       Impact factor: 5.555

4.  The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation.

Authors:  Man Wai Tang; Kris A Reedquist; Samuel Garcia; Bea Malvar Fernandez; Veronica Codullo; Elsa Vieira-Sousa; Vincent Goffin; Anne Q Reuwer; Marcel T Twickler; Daniëlle M Gerlag; Paul-Peter Tak
Journal:  Rheumatology (Oxford)       Date:  2016-09-10       Impact factor: 7.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.